Kornimate/medical-research-clean huggingface dataset:
quantification of phosphorylated alpha-synuclein in cutaneous biopsies as a prospective biomarker in parkinson's disease

Conditions: REM Behavior Disorder; Parkinson Disease

Summary: this study aims to assess the levels of phosphorylated alpha-synuclein (p-syn) in patients with parkinson's disease and rem behavior disorder using a minimally invasive skin punch biopsy. it seeks to understand the natural progression of p-syn deposition over time to explore the potential of p-syn quantification as a biomarker for disease progression.

this is a prospective, longitudinal study involving 75 parkinson's disease patients and 25 patients with rem behavior disorder. each participant will undergo a baseline evaluation followed by follow-ups every six months over an 18-month period. the evaluations will include clinical assessments, neurologic exams, and skin biopsies from three locations. data will be collected on disease progression and the amount of p-syn in cutaneous nerve fibers.

Eligibility criteria:
inclusion criteria: 1. male and female 50 to 100 years of age 2. clinical confirmed diagnosis of parkinson\&#39;s disease or rem sleep behavior exclusion criteria: 1. clinical evidence of severe vascular disease (history of ulceration, poor wound healing or vascular claudication) 2. history of allergic reaction to lidocaine for local anesthesia needed for skin biopsies 3. use of blood thinners (plavix or aspirin used separately is allowed) 4. significantly impaired wound healing or history of scarring or keloid formation

Keywords: pd rbd
lipid emulsions and liver function - results after 5 years.

Conditions: Liver Failure; Parenteral Nutrition-Related Hepatitis

Summary: intravenous lipid emulsion (ile) is an essential component of parenteral nutrition (pn), but also one of the key risk factors for development of intestinal failure associated liver disease (ifald). the aim of the study was to analyse the influence of iles on liver function during long term pn.

intravenous lipid emulsion (ile) is an essential component of parenteral nutrition (pn), but also one of the key risk factors for development of intestinal failure associated liver disease (ifald). despite of many commercially available iles with hypothetically different impact on liver, a direct comparison of them has never been performed. therefore the aim of the study was to analyse the influence of iles on liver function during long term pn. ths study is a continuation of the previous trial, nct03044639.

Eligibility criteria:
inclusion criteria: * ≥ 18 years of age, * chronic intestinal failure on pn including lipids, * metabolic stability (the absence of pathological laboratory resulting in the change of pn regime for at least one month) * ability to tolerate up to 1.0 g lipids/kg body weight per day as a part of pn exclusion criteria: * preexisting liver dysfunction (an elevation of sgot, sgtp, total bilirubin, ggtp, alkaline phosphatase of more than 3 times x normal value), * patients with a history of cancer and anti-cancer treatment within the last 5 years, * severe hyperlipidemia, * severe coagulopathy, * severe renal insufficiency, * acute thromboembolic events, * positive test for hiv, hepatitis b or c (from medical history), * known or suspected drug or alcohol abuse, * participation in another interventional clinical trial in parallel or within three months prior to the start of this clinical trial, * for women with childbearing potential (i.e. females who are not chemically or surgically sterile or females who are not postmenopausal) or women of childbearing potential tested positive on standard pregnancy test (urine dipstick) or/and lactation.
study of danicopan in participants with paroxysmal nocturnal hemoglobinuria (pnh)

Conditions: Paroxysmal Nocturnal Hemoglobinuria (PNH)

Summary: the purpose of this study was to determine the safety and efficacy of ach-0144471 (also known as danicopan and alxn2040) in currently untreated participants with pnh.

after 12 weeks of treatment, participants deriving clinical benefit were offered enrollment in a separate long-term extension study (ach471-103, nct03181633).

Eligibility criteria:
inclusion criteria: * currently untreated pnh participants with pnh type iii erythrocyte and/or granulocyte clone size ≥10% and anemia (hemoglobin \<12 grams/deciliter) with adequate reticulocytosis (as determined by the investigator). * ldh ≥1.5 x the upper limit of normal. * platelets ≥50,000/microliter without the need for platelet transfusions. * documentation of vaccination for neisseria meningitidis, haemophilus influenza, and streptococcus pneumoniae, or willingness to receive vaccinations during the screening period. * negative pregnancy test for females prior to dosing and throughout the study. exclusion criteria: * history of a major organ transplant (for example, heart, lung, kidney, liver) or hematopoietic stem cell/marrow transplant. * participants who had received another investigational agent within 30 days or 5 half-lives of the investigational agent prior to study entry, whichever is greater. * participants who had received eculizumab at any dose or interval within the past 75 days before study entry. * participants with known or suspected complement deficiency. * participants with active bacterial infection or clinically significant active viral infection, a body temperature \>38°celsius, or other evidence of infection on day 1, or with a history of febrile illness within 14 days prior to first study drug administration. * history of meningococcal infection, or a first-degree relative or household contact with a history of meningococcal infection. * females who were pregnant, nursing, or planning to become pregnant during the study or within 90 days of study drug administration or participants with a female partner who was pregnant, nursing, or planning to become pregnant during the study or within 90 days of study drug administration.

Keywords: pnh paroxysmal hemoglobinuria
protein intake & insulin action

Conditions: Obesity

Summary: the purpose of this proposal is to determine whether dietary protein restriction has beneficial effects on skeletal muscle insulin sensitivity and β-cell function in obese men and women.

insulin resistance, impaired pancreatic β-cell function, and diabetes are important complications associated with obesity. although excess energy intake and body fat accumulation are considered the major culprits responsible for obesity-associated metabolic abnormalities, it is possible that insulin resistance and impaired β-cell function are also due to increased dietary protein intake. protein intake is \~15 to 25% greater in obese than lean adults and exceeds the current institute of medicine recommended daily allowance (rda) of 0.8 g protein/kg body weight by \~75%. an increase in habitual protein intake of only 10 to 40%, assessed using dietary recall methods, been shown to increase the risk of developing diabetes by up to 2.2 fold. additionally, the ability to stimulate glucose disposal during insulin infusion is reported to be impaired in individuals consuming double the recommended protein intake as part of an isoenergetic diet. however, it is not known whether decreasing protein intake can improve insulin sensitivity and β-cell function in weight-stable, obese individuals. accordingly, obese men and women will be randomized to 8 weeks of treatment with a weight maintaining diet containing either i) 0.8 g protein/kg body weight (as recommended by the institute of medicine; protein restriction group)or ii) 1.4 g protein/kg body weight (control group). all subjects will receive a standardized "base-diet" with or without protein supplementation to avoid potential food selection bias that could confound the results when using high- and low-protein diets.

Eligibility criteria:
inclusion criteria: * body mass index (bmi) between 30 and 50 kg/m2 * subjects who are sedentary (\<1.5 h of exercise/week) * subjects with a high habitual protein intake (\>1.2 g/kg body mass/day) exclusion criteria: * subjects with evidence of significant organ system dysfunction (e.g. diabetes, severe cardiovascular disease, hyperlipidemia, cirrhosis, hypogonadism, uncontrolled hypo- or hyperthyroidism; uncontrolled hypertension) * subjects with metal implants * individuals with cancer or cancer that has been in remission for \<5 years, * individuals with dementia, * individuals who use tobacco products, * subjects who are taking medications known to affect glucose metabolism (e.g., steroids), * subjects taking medications to control certain medical conditions (e.g., hypertension) will be included if the drug regimen has been stable for at least 6 months before entering the study and is not expected to change during the study. * women who are pregnant due to changes in body composition and decreases in insulin sensitivity caused by pregnancy
effect of using same dermatome li̇ne for all port si̇tes in laparoscopic appendectomy in acute apandicitis

Conditions: Appendicitis

Summary: acute apandicitis is the one of most common cause of abdominal pain.most of center still use open appendectomy(oa) technic for acute apandisitis.but semm was defined laparoskopic appendectomy(la) with 3 ports in 1983.today surgeons skill and experience ara increasing about la day by day. because of advantages of la , this technical tend to be gold standart in acute apandisitis. in la , all of centers use same technic as 3 ports for the surgery. port sites located 1 infraumbilical , 1 right lower quadrant and 1 left lower quadrent in this surgery. but 3 dermatome lines have been effected in this style of location .this 3 points causes more pain postoperatively.in our study we will define the port locations into the same dermatome line (t10) . purpose of this research is incerasing the postoperative pain score ,decreasing postoperative need of analgesia and develop the patient satisfy.

most of surgeon use 3 port sites for the laparoscopic appendectomy in acute apandisitis. one of them places to infraumbilical region.,the other ports place to 1 right lower quadrant and 1 left lower quadrent routinly. in this study we will define t10 dermatome lregion in 40 patients who are planing to laparoscopic appendectomy because of acute apandisitis older than 18 years old , before the surgery . all of la port sites will put in this region .one of the port will put in infraumbilical site and the other ones will put 10 cm right and left side from infraumbilical port. in control group classic la port sites will be used in the surgery for 40 patients.these two groups will compare after the surgery by visual analog scala (vas) postoperative pain quantity will save by using vas. measurements will save in 1 hour,2 hour , 6 hour ,12 hour and 24 hour. all patients will take the same pain relief medication peroperatively and postoperatively. if the pain score would be more than 3 in vas , all patient will take additional analgesic doses.patients and vas researcher will not know the patients group .study will do as double blind.

Eligibility criteria:
inclusion criteria: * the patients who will undergo to laparoscopic appendectomy for acute apandisitis older than 18 years old. exclusion criteria: * perforated apandisitis * plastrone apndisitis

Keywords: dermatome laparoscopic appendectomy
handling oxygenation targets in the intensive care unit

Conditions: Hypoxemic Respiratory Failure; Oxygen Toxicity

Summary: handling oxygenation targets (hot) is standard of care in the intensive care unit (icu), however the quality and quantity of evidence is low and potential harm has been reported. the aim of the hot-icu trial is to assess the overall benefits and harms of two levels of oxygenation targets in adult critically ill patients with acute hypoxaemic respiratory failure in the icu.

acutely ill adults with hypoxaemic respiratory failure admitted to the intensive care unit (icu) are at risk of life-threatening hypoxia, and thus oxygen is administered. however, the evidence on the optimal level of oxygenation is of low quantity and quality with no firm evidence for benefit or harm. importantly, liberal use of supplementary oxygen may increase the number of serious adverse events including death. the aim of the hot-icu trial is to assess the benefits and harms of two targets of partial pressure of oxygen in arterial blood (pao2) in guiding the oxygen administration in acutely ill adults with hypoxaemic respiratory failure at icu admission.

Eligibility criteria:
inclusion criteria: * acutely admitted to the icu and * aged ≥ 18 years and * receives supplemental oxygen with a flow of at least 10 l per minutes in an open system including high-flow systems or at least a fio2 of 0.50 in a closed system including invasive or non-invasive ventilation or cpap systems and * expected to receive supplemental oxygen for at least 24 hours in the icu and * having an arterial line for pao2 monitoring exclusion criteria: * cannot be randomised within twelve hours after present icu admission * chronic mechanical ventilation for any reason * use of home oxygen * previous treatment with bleomycin * organ transplant during current hospital admission * withdrawal from active therapy or brain death deemed imminent * fertile woman (\< 50 years of age) with positive urine human gonadotropin (hcg) or plasma-hcg * carbon monoxide poisoning * cyanide poisoning * methaemoglobinaemia * paraquat poisoning * any condition expected to involve the use of hyperbaric oxygen (hbo) * sickle cell disease * consent not obtainable according to national regulations * previously randomised into the hot-icu trial

Keywords: oxygenation acute respiratory distress syndrome mechanical ventilation critical illness critical care
early maladaptive schemas in french health care professionals with burn out

Conditions: Burn Out

Summary: the purpose of this study is to compare the profiles and domains of maladaptive early schemas in care professionals with burnout symptoms with care professionals without burnout symptoms and with care non-professionals with burnout symptoms.

this is an ambispective, non-interventional, comparative, multicentre study in france. participants who are care professionals without burn out and care non-professionals with burn out will be matched in age (± 2 years) and gender to participants who are care professionals with burn out. the study population will be made up of care professionals in a state of burn out, care professionals without a state of burn out, and care non-professionals in a state of burn out.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years ; * state of burnout (at least one of the 3 dimensions of the maslach burnout inventory) for care professionals and non-professionals in a state of burnout and absence of a state of burnout for the group of care professionals without a state of burnout; * membership of a social security scheme; * patient having been informed and having given his/her oral non-opposition. exclusion criteria: * characterised psychiatric pathology pre-existing the burn out state for the burn out groups and characterised psychiatric pathology for the no burn out group; * participation in another clinical trial, or in a period of exclusion from another clinical trial; * participant under guardianship, curatorship or deprived of liberty.
safety and efficacy of proellex in pre-menopausal anemic women with symptomatic uterine fibroids

Conditions: Uterine Fibroids; Anemia

Summary: eligible female subjects will be randomly assigned to one of the three treatment groups. subjects will receive 325 mg (65 mg elemental iron) iron supplements to be taken twice daily during study drug treatment. the study duration is approximately six months, which is comprised of a 4 - 6 week screening period, a three-month drug treatment period, and a one-month follow-up period.

eligible female subjects will be randomly assigned to one of the three treatment groups. subjects will receive 325 mg (65 mg elemental iron) iron supplements to be taken twice daily during study drug treatment. the study duration is approximately six months, which is comprised of a 4 - 6 week screening period, a three-month drug treatment period, and a one-month follow-up period. study was terminated by clinical hold.

Eligibility criteria:
inclusion criteria: * female, between the ages of 18 and 48 years with body mass index (bmi) between 18 and 39, inclusive; * anemic, defined as hemoglobin levels less than or equal to 10.5 g/dl and uterine fibroid-associated symptoms indicated by a history of excessive menstrual bleeding; * surgical interventions for uterine fibroids (e.g. hysterectomy or myomectomy) planned or anticipated after the study; * willing to comply with all study procedures, including the endometrial biopsies and blood draws for all visits, including follow-up visits exclusion criteria: * post-menopausal women or women likely to become post-menopausal during the study, defined as one or more of the following: * six months or more (immediately prior to screening visit) without a menstrual period, or * prior hysterectomy, or * prior bilateral oophorectomy (unilateral oophorectomy is not exclusionary if regular menstruation is occurring); * females who have undergone a uterine arterial embolization, or endometrial ablation therapy (previous myomectomy is acceptable) for any cause; * documented endometriosis or active pelvic inflammatory disease (pid); * having a diagnosis, or suspected diagnosis, of carcinoma of the breast or reproductive organs; * known active infection with hiv, hepatitis a, b or c, gonorrhea, or chlamydia; * use of prohibited concomitant medications: 1. depo-provera use must cease ten months prior to first dose of study drug, or 2. gnrh agonists use (e.g. lupron depot) must cease six months prior to first dose of study drug, or 3. oral contraceptive or other hormonal treatments use must cease for 30 days prior to the start of the study

Keywords: uterine fibroids anemia
immediate effect of dynamic stretching with and without floss band on flexibility of hamstrings in futsal players

Conditions: Sports Physical Therapy

Summary: to compare the immediate effect of dynamic stretching with and without floss band on the hamstring flexibility in futsal players.

futsal is a soccer-like indoor sport that has been gaining popularity worldwide.to increase the flexibility and rom of involved muscle group a new method has been introduced named flossing of tissue by using a floss band. this research study will be helpful to enable therapists to broaden their treatment plans or choose better treatment tools for improving hamstrings flexibility in futsal players. thus, this study has been designed with the purpose to examine the effect of dynamic stretching with and without floss band on the flexibility of the hamstring.

Eligibility criteria:
inclusion criteria: * national level futsal players. * active for past 3 months. exclusion criteria: * players with any systemic disease/disorder. * players with any recent ligamentous or musculoskeletal injury that isn't healed yet.

Keywords: dynamic stretching flexibility flossing hamstring muscles soccer sports injuries
ophthalmologic evaluation of radiation-related optic neuropathy following image guided intensity-modulated radiation therapy (imrt) for nasopharyngeal carci̇noma

Conditions: The Aim of Our Study is to Prospectively Evaluate the Optic Neuropathy in Nasopharynx Cancer Patients

Summary: primary treatment in nasopharynx cancers is radiotherapy (rt) or chemoradiotherapy (crt) depending on the stage of the tumor. according to the guidelines, the dose of radiotherapy for primary tumors varies between 66-70 gy. in consideration of modern radiotherapy techniques like imrt with systemic chemotherapy for nasopharyngeal cancer, loco-regional control has been perfect. however, the rate of late complications from treatment, many of which are irreversible, is still high. radiation-related optic neuropathy is the late complication that optic nerves might be affected during the radiotherapy due to the close location of the nasopharynx. incidence of this is 8.7-9% in head and neck cancer and is observed between 2-9 years after rt. painless, irreversible, and progressive vision loss usually occurs, and the pallor of optic disc margins, retinal vein dilatation, bleeding, and neovascularization are in the ophthalmic examination. the risk of optic neuropathy increases when the tumor is in close contact with optic nerves, radiation dose, concurrent chemotherapy used, history of diabetes or hypertension. the aim of our study is to prospectively evaluate optic neuropathy in nasopharynx cancer patients treated in our clinic.


Eligibility criteria:
inclusion criteria: patient with nasopharyngeal carcinoma that histopathologically confirmed age \>18 radiotherapy or chemoradiotherapy applied to the patient in our clinic no recurrence or metastasis during follow-up optic evaluation evaluation with mri or ct during follow-up exclusion criteria: cranial rt no histopathological verification age\< 18 there were locoregional recurrence or metastasis

Keywords: radiation-related optic neuropathy,nasopharyngeal carci̇noma, radiotherapy
efficacy of metformin for sputum conversion in patients with active pulmonary tuberculosis

Conditions: Tuberculosis, Pulmonary

Summary: this study was a randomized controlled trial studying about acid-fast bacillus sputum conversion ratio from positive to negative of pulmonary tuberculosis patients between metformin with pulmonary tuberculosis standard treatment group and placebo drug with pulmonary tuberculosis standard treatment.

1. pulmonary tuberculosis patients with presence of at least one acid-fast bacillus in the sputum will be examined by an internist. 2. collect the necessary basic information of patients who agree to participate in the treatment such as complete blood count, blood urea nitrogen, creatinine, liver function test, fasting plasma glucose, hemoglobina1c, lactate, and gene expression signature for tuberculosis. 3. patients will be randomized into 2 groups: those who will receive metformin with pulmonary tuberculosis standard treatment and those who will receive placebo drug with pulmonary tuberculosis standard treatment. 4. patients will get a chest x-ray and collect sputum acid fast bacillus, sputum culture for tuberculosis and collect blood sample laboratory such as complete blood count, liver function test, creatinine, fasting plasma glucose, lactate, and gene expression signature for tuberculosis at second week. 5. patients will get a chest x-ray and collect sputum acid fast bacillus, and sputum culture for tuberculosis at second month. 6. patients will get a chest x-ray and collect sputum acid fast bacillus, and sputum culture for tuberculosis at fifth month. 7. patients will get a chest x-ray and collect sputum acid fast bacillus, and sputum culture for tuberculosis at sixth month. 8. after collecting all information of patients, investigators will analyze in clinical and statistical analysis.

Eligibility criteria:
inclusion criteria: * age more than 18 years old * be diagnosed pulmonary tuberculosis compatible with clinical and chest x ray by an internist * presence of at least one acid -fast bacillus in the sputum * recieve pulmonary tuberculosis standard treatment compose of isoniazid, rifampicin, pyrazinamide and ethambutol * bmi more than 18.5 kg/m2 * reserach participants were diagnosed diabetes or non diabetes. * research participants or representatives are welcome to join the project by signing. exclusion criteria: * pregnancy * organ transplants * egfr less than 45 ml/min/1.73 m2 * ast, alt or total bilirubin more than three times * researh participants have received metformin at least 2 weeks before joining the project. * immunocompromised host such as patient receive systemic immunosuppressive drugs or systemic chemotherapy. * research participant or his representative refuses or requests to withdraw,

Keywords: tuberculosis metformin